145 related articles for article (PubMed ID: 8596489)
1. Oral glucose ingestion stimulates cholecystokinin release in normal subjects and patients with non-insulin-dependent diabetes mellitus.
Hasegawa H; Shirohara H; Okabayashi Y; Nakamura T; Fujii M; Koide M; Otsuki M
Metabolism; 1996 Feb; 45(2):196-202. PubMed ID: 8596489
[TBL] [Abstract][Full Text] [Related]
2. Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.
Liddle RA; Rushakoff RJ; Morita ET; Beccaria L; Carter JD; Goldfine ID
J Clin Invest; 1988 Jun; 81(6):1675-81. PubMed ID: 3290250
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.
Schmidt WE; Creutzfeldt W; Höcker M; Nustede R; Choudhury AR; Schleser A; Rovati LC; Fölsch UR
Eur J Clin Invest; 1991 Oct; 21(5):501-11. PubMed ID: 1752290
[TBL] [Abstract][Full Text] [Related]
4. High plasma cholecystokinin response following ingestion of test meal by patients with non-insulin dependent diabetes mellitus.
Nakano I; Funakoshi A; Shinozaki H; Miyazaki K; Ibayashi H; Tateishi K; Hamaoka T
Regul Pept; 1986 May; 14(3):229-36. PubMed ID: 3726174
[TBL] [Abstract][Full Text] [Related]
5. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
Hildebrand P; Ensinck JW; Ketterer S; Delco F; Mossi S; Bangerter U; Beglinger C
J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712
[TBL] [Abstract][Full Text] [Related]
6. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W
Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
[TBL] [Abstract][Full Text] [Related]
7. Effects of cholecystokinin receptor blockade on circulating concentrations of glucose, insulin, C-peptide, and pancreatic polypeptide after various meals in healthy human volunteers.
Niederau C; Schwarzendrube J; Lüthen R; Niederau M; Strohmeyer G; Rovati L
Pancreas; 1992; 7(1):1-10. PubMed ID: 1557335
[TBL] [Abstract][Full Text] [Related]
8. Effect of added fat on plasma glucose and insulin response to ingested potato in individuals with NIDDM.
Gannon MC; Ercan N; Westphal SA; Nuttall FQ
Diabetes Care; 1993 Jun; 16(6):874-80. PubMed ID: 8325201
[TBL] [Abstract][Full Text] [Related]
9. Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans.
Rushakoff RJ; Goldfine ID; Carter JD; Liddle RA
J Clin Endocrinol Metab; 1987 Sep; 65(3):395-401. PubMed ID: 3305550
[TBL] [Abstract][Full Text] [Related]
10. Determination of plasma cholecystokinin (CCK) concentrations by bioassay and radioimmunoassay in man. A critical evaluation.
Höcker M; Schmidt WE; Creutzfeldt W; Choudhury AR; Nustede R; Schafmayer A; Fölsch UR
Regul Pept; 1992 Feb; 37(3):255-69. PubMed ID: 1557514
[TBL] [Abstract][Full Text] [Related]
11. Reduced postprandial cholecystokinin (CCK) secretion in patients with noninsulin-dependent diabetes mellitus: evidence for a role for CCK in regulating postprandial hyperglycemia.
Rushakoff RA; Goldfine ID; Beccaria LJ; Mathur A; Brand RJ; Liddle RA
J Clin Endocrinol Metab; 1993 Feb; 76(2):489-93. PubMed ID: 8432795
[TBL] [Abstract][Full Text] [Related]
12. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Jones IR; Owens DR; Luzio S; Williams S; Hayes TM
Diabetologia; 1989 Sep; 32(9):668-77. PubMed ID: 2676668
[TBL] [Abstract][Full Text] [Related]
13. Meal-related changes in plasma CCK bioactivity in patients with chronic pancreatitis.
Nakamura T; Tando Y; Yamada N; Imamura K; Ishii M; Terada A; Takebe K; Kaji A; Watanabe T; Suda T; Koide M; Otsuki M
Acta Gastroenterol Belg; 1998; 61(4):400-6. PubMed ID: 9923089
[TBL] [Abstract][Full Text] [Related]
14. Effect of atropine on the plasma cholecystokinin response to intraduodenal fat in man.
Hopman WP; Jansen JB; Lamers CB
Digestion; 1984; 29(1):19-25. PubMed ID: 6724165
[TBL] [Abstract][Full Text] [Related]
15. Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.
Liddle RA; Gertz BJ; Kanayama S; Beccaria L; Gettys TW; Taylor IL; Rushakoff RJ; Williams VC; Coker LD
J Clin Endocrinol Metab; 1990 May; 70(5):1312-8. PubMed ID: 2186058
[TBL] [Abstract][Full Text] [Related]
16. [Effect of CCK receptor antagonists on plasma CCK bioassay].
Sun G; Pan GZ; Ma F; Wen SH; Du SF
Sheng Li Xue Bao; 1992 Dec; 44(6):609-13. PubMed ID: 1302379
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the effects of equal amounts of fat, protein, and starch on plasma cholecystokinin in man.
Hopman WP; Jansen JB; Lamers CB
Scand J Gastroenterol; 1985 Sep; 20(7):843-7. PubMed ID: 4048835
[TBL] [Abstract][Full Text] [Related]
18. Insulin deficiency in non-insulin-dependent diabetes.
Temple RC; Carrington CA; Luzio SD; Owens DR; Schneider AE; Sobey WJ; Hales CN
Lancet; 1989 Feb; 1(8633):293-5. PubMed ID: 2563455
[TBL] [Abstract][Full Text] [Related]
19. Effects of three different cholecystokinin receptor antagonists on basal and stimulated insulin and glucagon secretion in mice.
Karlsson S; Ahrén B
Acta Physiol Scand; 1989 Mar; 135(3):271-8. PubMed ID: 2648765
[TBL] [Abstract][Full Text] [Related]
20. CCK receptor antagonism by loxiglumide and gall bladder contractions in response to cholecystokinin, sham feeding and ordinary feeding in man.
Konturek JW; Konturek SJ; Kurek A; Bogdal J; Oleksy J; Rovati L
Gut; 1989 Aug; 30(8):1136-42. PubMed ID: 2767511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
